

1 **Supplementary Methods and Results**

2 **1. A new assay for phosphorylated tau protein (p-tau) in human plasma, which can**  
3 **detect both N- and C-terminally truncated p-tau181 (mid-p-tau181)**

4 As shown in Supplementary Figure 1, an anti-tau mouse monoclonal antibody against a  
5 mid-portion of tau protein ranging from 151 to 163 amino acid residues was coupled to  
6 paramagnetic beads (Quanterix) and used for the capture antibody. As a detector, we  
7 used the AT270 mouse monoclonal antibody (Invitrogen) specific for the threonine 181  
8 phosphorylation site. The detection antibody was conjugated to biotin following the  
9 manufacturer's instructions (Quanterix). We used the human p-tau181 standard in the  
10 Tau (Phospho) [pT181] Human ELISA Kit (Invitrogen) as the calibrator for our mid-p-  
11 tau181 assay. All plasma samples were diluted four times with the Tau Calibrator  
12 Diluent (Quanterix) prior to the assays to minimize matrix effects. The assay procedure  
13 followed that for the pTau-181 Advantage V2.1 Kit, except for changes to the capture  
14 antibody used as mentioned above. The details of the assay procedures have been  
15 described previously (Shinomoto et al. 2021; Satoh-Asahara et al. 2022). All plasma  
16 samples were run in duplicate with the same lot of standards. Fluorescent signals were  
17 converted to average enzyme per bead (AEB) numbers as described previously (Tatebe  
18 et al. 2017) and then concentrations of plasma mid-p-tau181 were extrapolated from  
19 four-parametric logistic curves of AEBs generated with known calibrator  
20 concentrations.

21 Plasma mid-p-tau181 levels were measured using the previously described assay  
22 on the Simoa HD-X Analyzer (Quanterix) at the National Institutes for Quantum  
23 Science and Technology. To ensure that measurements were performed in a blinded  
24 manner, unique identifiers that did not contain any participant-related information were  
25 attached to the blood sample tubes sent from the clinical department to the investigator  
26 who measured the plasma mid-p-tau levels. The samples were decoded only after data  
27 sharing with the participating clinical scientists had been completed. Internal quality  
28 control samples were analyzed in duplicates at the start and end of each run to  
29 determine within- and between-run variations.

30  
31 **2. Validation of the newly developed mid-p-tau181 assay**

32 **2-1. Standard curve for the mid-p-tau181 immunoassay**

33 Supplementary Figure 2 shows the standard curve for our novel mid-p-tau181 assay,  
34 demonstrating that mid-p-tau181 was detected with high sensitivity. The curve was  
35 generated by analyzing the p-tau181 standard in the Tau (Phospho) [pT181] Human  
36 ELISA Kit (Invitrogen) in duplicate measures and fitting the digital signals on a four-

1 parameter logistic curve. The goodness of fit was 0.9999.

## 2 3 **2-2. Limit of detection (LOD) and lower limit of quantification (LLOQ)**

4 We prepared 16 aliquots of blank sample (Tau Calibrator Diluent) and measured  
5 “background” signals of our novel plasma mid-p-tau181 assay on the Simoa HD-X  
6 Analyzer (Quanterix). Signals measured on the Simoa Analyzer were quantified by a  
7 common unit, namely average number of enzymes labels per bead (AEB). Thereafter,  
8 the LOD of the assay was determined as an interpolated mid-p-tau181 concentration  
9 derived from the mean plus 2.5 SD value of AEBs for the blank samples. The LOD of  
10 the assay, which requires 50  $\mu$ L of plasma, was 0.1144 pg/mL.

11 The LLOQ of the assay was determined as an interpolated p-tau concentration  
12 derived from the mean plus 10 SD value of AEBs for blank samples. The LLOQ of the  
13 assay was 0.3770 pg/mL.

## 14 15 **2-3. Intra-assay precision**

16 Twenty samples with different concentrations (0.039, 6.25, 25, and 100 pg/mL) of  
17 recombinant p-tau181 were prepared for analysis of intra-assay precision, and measured  
18 AEBs in one experiment. Intra-assay precision was determined by calculating within-  
19 run coefficient of variation (CV) for those samples.

20 Intra-assay precision was robust with CVs between 1.1% and 3.5 %  
21 (Supplementary Table 1).

## 22 23 **2-4. Inter-assay precision for quality controls and repeatability of the standard** 24 **curve**

25 We prepared three recombinant p-tau samples and two plasma samples with  
26 different plasma mid-p-tau181 concentrations for quality control experiments and  
27 measured the mid-p-tau181 levels in those samples five times on different days. Inter-  
28 assay precision was determined by calculating the CV of the AEB signals between the  
29 runs for those samples.

30 The %CV of the AEBs at different concentrations were 5.56, 5.09, 9.19, 5.30, and  
31 5.96 %, respectively (Supplementary Table 2). These results indicated that our novel  
32 mid-p-tau181 assay showed good inter-assay precision (< 10%).

## 33 34 **2-5. Dilution linearity**

35 To explore dilution linearity, a plasma sample with a moderate mid-p-tau181  
36 concentration was used, and twofold serial dilutions ( $\times 2$ ,  $\times 4$ ,  $\times 8$ ,  $\times 16$ , and  $\times 32$ ) of the

1 sample were generated using the sample diluent until the theoretical concentration  
2 reached the LLOQ. Serially diluted samples were analyzed in duplicate.

3 The dilution linearity experiments demonstrated that an examined sample can be  
4 diluted to a concentration just below the LLOQ and still provide a reliable  
5 quantification after the serial dilution (Supplementary Figure 3).

## 7 **2-6. Spike recovery and parallelism**

8 For the spike recovery tests, four aliquots of each two plasma samples with different  
9 mid-p-tau181 concentrations were prepared and spiked with 0, 0.15, 0.3, and 0.6 pg of  
10 mid-p-tau181 in 360  $\mu$ L of solution (containing patient plasma, sample buffer, and  
11 spiked peptide). These eight ( $4 \times 2$ ) aliquots were analyzed in quadruplicate on the same  
12 run. To evaluate parallelism, two spike recovery curves were made, starting from the  
13 non-spiked solution to the 0.6 pg-spiked solution. Recovery rates (%Recovery) were  
14 calculated by subtracting the endogenous mid-pTau181 concentration from the  
15 measured concentration (Andreasson U, et al. Front Neurol. 2015; 6: 179).

16 In the spike recovery and parallelism experiments (Supplementary Figure 4),  
17 the recovery rate (%Recovery) of each sample was 84.4%–119.3% (Supplementary  
18 Table 3). The parallelism of two spike recovery curves starting from the non-spiked  
19 solution to the 0.6 pg-spiked solution is also shown in Supplementary Figure 4, with our  
20 data demonstrating that plasma samples spiked with 0, 0.15, 0.3, and 0.6 pg of mid-p-  
21 tau181 protein provided reliable recovery rates and parallelism.

## 23 **2-7. Comparison of AEB signals for N- and C-terminally truncated p-tau181** 24 **between the established p-tau181 assay and the new mid-p-tau181 assay developed** 25 **herein**

26 To confirm the ability of our new mid-p-tau assay to detect both N- and C-terminally  
27 truncated p-tau proteins, we compared our assay with the widely used and commercially  
28 available p-tau181 assay (Simoa™ pTau-181 Advantage V2 Kit, Quanterix). We  
29 prepared both N- and C-terminally truncated p-tau proteins as described in the  
30 following sections.

### 32 **2-7-1. cDNA construction**

33 The cDNA of tau (aa100–251) was generated from NΔR cDNA in PCI-neo (Takashima  
34 et al. 1998) according to the modified instructions of the PrimeSTAR® Mutagenesis  
35 Basal Kit (Takara Bio Inc., R046). Briefly, 2.5 ng of NΔR cDNA was mixed in  $1 \times$   
36 PrimeSTAR® Max DNA Polymerase (Takara Bio Inc., R045) containing 0.2  $\mu$ M of

1 forward primer (5'-CACCATGGGAACCACAGCTGAAGAAGCAGGC-3') and 0.2  
2  $\mu$ M of reverse primer (5'-GTGGTTCATGGTGGCGAATTCTCGAGGCTAG-3').  
3 PCR was performed on a C1000™ Thermal Cycler (BIO-RAD) with the following  
4 steps: an initial denaturation at 98°C for 2 min; 18 three-step cycles involving  
5 denaturation at 98°C for 10 s, annealing at 55°C for 15 s, and extension at 68°C for 90  
6 s; and a final extension at 68°C for 10 min. A PCR product was incubated with Dpn I  
7 (20 units) (New England Biolabs, R0176) at 37°C for 20 min to digest the template  
8  $\Delta$ R plasmid. cDNA of 100–251 tau was transformed into DH5 $\alpha$  (TOYOBO, DNA-  
9 903F). After the DH5 $\alpha$  was cultured in LB medium containing 10 mg/mL of tryptone  
10 (Gibco, 211705), 5 mg/mL of yeast extract (Gibco, 212750), 10 mg/mL of sodium  
11 chloride (Nacalai Tesque, 31320-05), and 100  $\mu$ g/mL of ampicillin (Nacalai Tesque,  
12 02739-32), the cDNA was purified by NucleoSpin® Plasmid Transfection-grade  
13 (Takara Bio Inc., 740490). The sequences of the cDNA were confirmed through DNA  
14 sequencing (FASMAC).

#### 15 16 **2-7-2. Cell culture**

17 COS-7 cells at around 90% confluence were detached from 10-cm dishes (CORNING,  
18 353003) by trypsinization (Nacalai Tesque, 32777-15) and counted. The cells were  
19 plated at  $2.0 \times 10^5$  in a 6-well plate (CORNING, 3506). cDNAs (2.5  $\mu$ g) were  
20 transfected with Lipofectamine 3000 according to the manufacturer's instruction  
21 (Invitrogen, L3000) 2 days after culturing. PCI-neo (Promega) was used as the empty  
22 vector. Transfection reagents were removed by a medium change 1 day after the  
23 transfection.

#### 24 25 **2-7-3. Preparation of cell homogenate**

26 The cells were scraped in a buffer (1  $\times$  TBS [Nacalai Tesque, 35438-81], 1 mM EDTA  
27 [Nacalai Tesque, 15112-22]) containing protease inhibitors (5  $\mu$ g/mL of pepstatin A  
28 [Nacalai Tesque, 26436-52, 5  $\mu$ g/mL of leupeptin [Nacalai Tesque, 103476-89-7],  
29 2  $\mu$ g/mL of aprotinin [Nacalai Tesque, 03346-84], and phosphatase inhibitors [Nacalai  
30 Tesque, 07575-51]) and homogenized for 30 s on the crushed ice using a polytron  
31 homogenizer (NITI-ON, NS-310E). After homogenization, solutions were centrifuged  
32 (23000 rpm, 15 min, 4°C) using a TLA55 Rotor (Beckman Coulter). The supernatants  
33 were applied to the Bradford assay (Nacalai Tesque, 11617-71) to determine the total  
34 protein concentration and then stored at  $-80^\circ\text{C}$ .

#### 35 36 **2-7-4. Comparison between our mid-p-tau181 assay and the commercially**

### 1 **available p-tau181 assay**

2 Serially diluted cell homogenates, prepared as previously described, containing both N-  
3 and C-terminally truncated p-tau181 were applied to our mid-p-tau181 assay  
4 (Supplementary Figure 5, a solid line) and a commercially available p-tau181 assay  
5 (Simoa™ pTau-181 Advantage V2 Kit, Quanterix). Fluorescent signals converted to  
6 AEB values obtained from both assays are plotted in the Supplementary Figure 5 (solid  
7 line: mid-p-tau assay; broken line: commercially available p-tau181 assay). The results  
8 from both assays demonstrated that AEB values were obtained in our mid-p-tau181  
9 assay but not in the commercially available p-tau181 assay, indicating that our mid-p-  
10 tau assay can quantify both N- and C-terminally truncated p-tau181 that could not be  
11 detected with the conventional p-tau181 assay.  
12

### 13 **3. Determining the cutoff values of temporal meta-ROI SUVR in tau PET images**

14 ROC analysis was conducted using tau PET images of CN subjects and AD  
15 continuum patients to determine the optimal cutoff value for the temporal meta-ROI  
16 SUVR. Our analysis provided an AUC of 0.924. Moreover, based on the Youden index,  
17 we obtained a sensitivity and specificity of 85.4% and 92.5%, respectively. The optimal  
18 cutoff value for discrimination was determined to be 1.105.  
19

20 Satoh-Asahara N, Yamakage H, Tanaka M, Kawasaki T, Matsuura S, Tatebe H,  
21 Akiguchi I, Tokuda T. Soluble TREM2 and Alzheimer-related biomarker  
22 trajectories in the blood of patients with diabetes based on their cognitive  
23 status. *Diabetes Res Clin Pract.* 2022; 193: 110121.

24 Shinomoto M, Kasai T, Tatebe H, Kitani-Morii F, Ohmichi T, Fujino Y, Allsop D,  
25 Mizuno T, Tokuda T. Cerebral spinal fluid biomarker profiles in CNS infection  
26 associated with HSV and VZV mimic patterns in Alzheimer's disease. *Transl*  
27 *Neurodegener.* 2021; 10(1): 2.

28 Tatebe H, Kasai T, Ohmichi T, Kishi Y, Takeya T, Waragai M, Kondo M, Allsop D,  
29 Tokuda T. Quantification of plasma phosphorylated tau to use as a biomarker for  
30 brain Alzheimer pathology: pilot case-control studies including patients with  
31 Alzheimer's disease and down syndrome. *Mol Neurodegener.* 2017; 12(1): 63.

32 Takashima A, Murayama M, Murayama O, Kohno T, Honda T, Yasutake K, Nihonmatsu  
33 N, Mercken M, Yamaguchi H, Sugihara S, Wolozin B. Presenilin 1 associates  
34 with glycogen synthase kinase-3beta and its substrate tau. *Proc Natl Acad Sci U*  
35 *S A.* 1998; 95(16): 9637-41.  
36

**Supplementary Table 1. Intra-assay precision (n = 20).**

	Sample 1: 0.039 pg/mL	Sample 2: 6.25 pg/mL	Sample 3: 25.0 pg/mL	Sample 4: 100 pg/mL
Mean AEB	0.00632	0.0580	0.224	0.872
SD	0.000222	0.000849	0.00656	0.00940
CV (%)	3.51	1.46	2.94	1.08

AEB, average enzyme per bead; SD, standard deviation; CV, coefficient of variation.

**Supplementary Table 2. Inter-assay precision for quality control samples (n = 25).**

	Sample 1	Sample 2	Sample 3	Sample 4	Sample 5
Mean AEB	0.00331	0.00484	0.0592	0.128	0.882
SD	0.000184	0.000246	0.00545	0.00676	0.0526
CV (%)	5.56	5.09	9.19	5.30	5.96

AEB, average enzyme per bead; SD, standard deviation; CV, coefficient of variation.

**Supplementary Table 3. Recovery rate (%Recovery) for each plasma sample in the spike recovery tests.**

	Treatment	Measured concentration (pg/mL)	CV (%)	Theoretical concentration of the spiked sample (pg/mL)	Recovery rate (%)
Sample 1	Neat (0 pg spike)	0.2675	14.9		
	0.15 pg spike	0.3500	7.94	0.4175	119.3
	0.3 pg spike	0.5130	12.2	0.5675	110.6
	0.6 pg spike	0.8649	7.73	0.8675	100.3
Sample 2	Neat (0 pg spike)	0.4516	6.91		
	0.15 pg spike	0.6842	3.63	0.6016	87.9
	0.3 pg spike	0.8909	5.82	0.7516	84.4
	0.6 pg spike	1.101	7.44	1.0516	95.6

CV, coefficient of variation.

**Supplementary Table 4. Multiple linear regression analysis of p-tau levels with amyloid and tau PET metrics.**

	Beta coefficient	Standard error	Adjusted R <sup>2</sup>	P-value
mid-p-tau181				
Amyloid PET (Centiloid)	0.399	0.118	0.420	0.002
Tau PET (Temporal meta-ROI)	0.311	0.118		0.020
N-p-tau181				
Amyloid PET (Centiloid)	0.258	0.115	0.450	0.056
Tau PET (Temporal meta-ROI)	0.472	0.115		<0.0001

**Supplementary Table 5. Tau PET status of cognitively normal individuals and AD continuum patients through three different approaches.**

Quantitative approach	CN		AD	
	Tau (-)	Tau (+)	Tau (-)	Tau (+)
Braak staging	35	5	3	45
Temporal meta-ROI SUVR	37	3	7	41
AD tau score	40	0	2	35

The cut-off values of Temporal meta-ROI SUVR and AD tau score were 1.105 and 0.1986, respectively. AD tau scores were exclusively computed for cases that underwent imaging with the mCT PET scanner.

1 **Legends for Supplementary Figures**

2 **Supplementary Figure 1. A schematic illustration tau protein showing the epitope**  
3 **location of the antibodies used in this study.**

4  
5 **Supplementary Figure 2. Standard curve.**

6 Refer “Supplementary Methods and Results”, “2-1. Standard curve for the mid-p-  
7 tau181 immunoassay”.

8  
9 **Supplementary Figure 3. Dilution linearity.**

10 Refer “Supplementary Methods and Results”, “2-5. Dilution linearity”.

11  
12 **Supplementary Figure 4. Spike recovery and parallelism.**

13 Refer “Supplementary Methods and Results”, “2-6. Spike recovery and  
14 parallelism”.

15  
16 **Supplementary Figure 5. Comparison of the AEB signals between our mid-p-  
17 tau181 assay and the commercially available p-tau181 assay.**

18 Refer “Supplementary Methods and Results”, “2-7-4. Comparison between our  
19 mid-p-tau181 assay and the commercially available p-tau181 assay”.

20  
21 **Supplementary Figure 6. List of ROIs applied to the tau PET images.**

22 From left to right, overlaid ROIs on native T1 space of representative subject: Braak  
23 staging ROI, temporal meta-ROI, and AD tau score ROI. The Braak staging ROI is  
24 color-coded, with Braak I/II, III/IV, and V/VI regions shown in red, yellow, and blue,  
25 respectively. The temporal meta-ROI is labeled in green. The AD tau score ROI  
26 represents 114 areas segmented using Mvision. Scores were derived by assigning  
27 weights to diagnostically relevant areas within these ROIs.

28  
29 **Supplementary Figure 7. Comparative analyses of blood biomarkers across the**  
30 **clinical diagnosis groups and between the amyloid PET status.**

31 (A) The data distribution is portrayed using scatter plots, with group differences having  
32 been evaluated through the Kruskal–Wallis test. Statistically significant differences are  
33 denoted as follows:  $p < 0.0001$  (\*\*\*\*),  $p = 0.0004$ , or  $0.0010$  (\*\*\*),  $p = 0.0070$  (\*\*),  
34 and non-significant at  $p < 0.05$  (ns), as determined using Dunn's multiple comparisons.

35 (B) ROC curves were utilized to differentiate AD from other groups determined  
36 according to qualitative findings of amyloid PET. The corresponding AUC values are



1 listed.  
2 CN, cognitively normal; AD, Alzheimer's disease; PSP, progressive supranuclear palsy;  
3 FTLD, frontotemporal degeneration; A $\beta$ , amyloid beta; N-p-tau181, phosphorylated  
4 tau181 measured with the Simoa pTau-181 V2.1 Assay kit (Quanterix); mid-p-tau181,  
5 phosphorylated tau181 measured using the originally developed immunoassay directed  
6 to both N- and C-terminally truncated p-tau181 fragments; NfL, neurofilament light  
7 chain; ROC, Receiver Operating Characteristic; AUC, area under the ROC curve.

8

9 **Supplementary Figure 8. Correlations between plasma mid-p-tau levels and tau**  
10 **PET measures in the subjects with PSP.**

11 Correlation analysis between tau PET images and plasma mid-p-tau181 levels in  
12 patients with PSP. Neither voxel-based (A) nor ROI-based (B and C) analyses showed a  
13 significant correlation with tau PET accumulation. The ROI-based approach used  
14 Pearson's correlation, with the results presented as r (correlation coefficient) and p  
15 (statistical significance) values. PSP-tau score is a machine learning-based measure  
16 indicating PSP-related features of tau PET images (Endo et al. 2022). Each anatomical  
17 ROI was set in MNI space using a template atlas (Talairach Daemon atlas from the  
18 Wake Forest University PickAtlas version 3.0.5).  
19 SUVR, standardized uptake value ratio.

20

21

22

23